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a  b  s  t  r  a  c  t
We  report  on the  synthesis  of  novel  Ru(II)  compounds  (Ru-1  to Ru-8)  bearing  R-pdc,  4-Cl-pbinh
ligands (where  R  = 4-CF3, 4-F, 4-OH  pdc =  3-phenyl-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide,  pbinh  =  phenoxybenzylidene  isonicotinyl  hydrazides)  and  their  in vitro  antitumor
activity  toward  the  cell  lines  murine  leukemia  L1210,  human  lymphocyte  CEM,  human  epithelial  cervical
carcinoma  HeLa,  BEL-7402  and  Molt4/C8.  Some  of  the complexes  exhibited  more  potent  antiprolifer-
ative  activity  against  cell  lines  than the  standard  drug  cisplatin.  Ruthenium  complex  Ru-2  displayedeywords:
ntiproliferative
ovine serum albumin
NA-binding
u(II) compounds
potent  cytotoxicity  with  than  that of  cisplatin.  DNA-binding,  DNA  cleavage  and  protein  binding  proper-
ties  of ruthenium  complexes  with  these  ligands  are  reported.  Interactions  of  these  ruthenium  complexes
with  DNA  revealed  an  intercalative  mode  of binding  between  them.  Synchronous  ﬂuorescence  spectra
proved  that  the interaction  of  ruthenium  complexes  with  bovine  serum  albumin  (BSA)  resulted  in a
conformational  change  of the  latter.
© 2015  Elsevier  B.V.  All  rights  reserved.. Introduction
The ﬁeld of anticancer metallodrugs is dominated by platinum
ased compounds and the so-called “DNA paradigm”, which
resumes that the mechanism of action of metallodrugs relies
n direct DNA damage [1]. The quest for alternative drugs to the
ell-known cisplatin and its derivatives, which are still used in
ore than 50% of the treatment regimes for patients suffering from
ancer, is highly needed [2,3]. The development of more efﬁcient
nticancer drugs with better selectivity and diminished toxic side
ffects is currently an area of intense research. With the objective
f developing compounds with a new mode of action in compar-
son to the established anticancer drugs cisplatin, carboplatin,
nd oxaliplatin for treatment of a broader range of tumors and
ith fewer side effects, many metal complexes were investigated
n recent years for their tumor inhibiting properties [4]. New
etal-based anticancer drugs may  be able to widen the spectrum
∗ Corresponding author at: FIOCRUZ/CDTS, Av. Brasil, 4035, Prédio da Expansão,
◦ Andar Sala 814, Manguinhos, Rio de Janeiro, RJ 21040-361, Brazil.
E-mail addresses: sthota@cdts.ﬁocruz.br, stsreekanththota@gmail.com
S. Thota).
ttp://dx.doi.org/10.1016/j.ijbiomac.2015.09.045
141-8130/© 2015 Elsevier B.V. All rights reserved.of treatable cancers, reduce toxic side effects, and overcome
platinum resistance. Interest in bio-organometallic chemistry and
the design of organometallic complexes as anticancer agents is
currently increasing [5]. In order to achieve a modiﬁed mechanism
of activity, several approaches were considered promising; e.g.,
the exchange of platinum centers by other metals, and conjugation
of metallodrugs to proteins or other biomolecules as targeting
concepts [6]. Another concept for improving the chemotherapeu-
tic activity was realized by replacing the platinum center with
ruthenium. So far only two Ru(III) coordination compounds have
reached clinical trials, NAMI-A {H2Im[trans-RuCl4(DMSO)(Him)]
(HIm) imidazole}  and KP1019 {H2Ind[trans-RuCl4(HInd)2] (HInd)
indazole}, and both of them are considered promising drug can-
didates [7,8]. Binding to plasma proteins [9] and the reduction of
Ru(III) to Ru(II) [10] seem to be key steps in their mode of action
and the thereby-mediated degree of selectivity is regarded as a
reason for their low general toxicity. The organometallic Ru(II)
arene complexes, with the half-sandwich type structure, have
demonstrated their potential increasingly [11]. Their coordination
sites can be ﬁlled with various ligands, which offer numerous pos-
sibilities to modulate biological and pharmacological properties
by proper ligand selection [12]. Due to their conspicuous structure
these ruthenium complexes are also often called “piano-stool”
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omplexes. The arene ligand stabilizes the bioactive Ru(II) state.
hile some of the (arene) Ru(II) compounds bind to DNA and,
hus, feature indeed ruthenium-based cisplatin analogs, other
omplexes rather possess modes of action similar to NAMI-A
nd attack metastases while being widely non-toxic to cancer
ells in vitro [13]. Ruthenium complexes bearing ligands such as
,2′-bipyridine (bpy) and 1,10-phenanthroline (phen) are widely
sed in bioinorganic chemistry as anticancer agents [14–24].
n vitro cytotoxicity, cell migration and apoptotic mechanism
tudies induced by ruthenium(II) complexes [25,26]. Since DNA is
articularly sensitive to oxidative cleavage, the vast majority of the
tudies on metallonucleases has focused mainly on the molecules
hat cleave DNA oxidatively. Hence, it is clear that the nature
f the ligand as well as the identity and oxidation state of the
etal play pivotal roles in their interaction with DNA molecule.
hese ruthenium complexes possess excellent in vitro cytotoxic
ctivities; the corresponding ligands are not as cytotoxic. The
elationship between anticancer potency and the DNA-binding
fﬁnity was analyzed to get possible QSAR, but the anticancer
fﬁciency is not in line with DNA-binding afﬁnity [27]. In this
anuscript we report on a study of a ruthenium complexes of
he type [Ru(phen)2(4-CF3-pdc)]2+Cl2, [Ru(phen)2(2-F-pdc)]2+Cl2,
Ru(bpy)2(2-OH-pdc)]2+Cl2, [Ru(bpy)2(4-Cl-pbinh)]2+Cl2 (where
dc = 3-phenyl-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole-
-carbothioamide, pbinh = phenoxybenzylidene isonicotinyl
ydrazides). We  report the synthesis and characterization of the
omplexes DNA binding, DNA cleavage and their cytotoxicity
oward a various cancer cell lines.
. Experimental
.1. Materials and methods
All the chemicals were purchased from Sigma–Aldrich and Alfa
esar and used without further puriﬁcation. Calf thymus DNA (CT-
NA) was obtained from Sigma–Aldrich. All the melting points
ere determined in open capillary and are uncorrected. Absorp-
ion measurements (200–800 nm)  on all of the complexes in PBS
uffer solutions were performed at room temperature using an
nalytikjena UV-Specord 210 plus (edition 2010) UV–vis spec-
rophotometer. FTIR spectra were recorded in infrared spectra
etween 400 and 4000 cm−1 were obtained at room temperature
ith a resolution of 1 cm−1 using a Bruker-alpha spectrometer.
H, and 13C NMR  measurements were carried out in DMSO-
6 solutions on Bruker Avance III spectrometers, operating at
ither 400 or 600 MHz  and equipped with self-shielded z-axis
ulsed ﬁeld gradient dual broadband direct observation probe-
eads. Chemical shifts were referenced to residual solvent peaks,
nd the temperature was calibrated using a methanol sample.
AB mass spectra were recorded on a JEOL JMS600 spectrometer
ith an m-NBA matrix. Microanalysis (C, H, and N) was per-
ormed with a vario MICRO CUBE elemental analyzer. All synthetic
anipulations were carried out under dry oxygen-free nitrogen
tmosphere using standard Schlenk techniques. The solvents were
istilled from the appropriate drying agents and degassed before
se.
Pyrazoline ligands(R-pdc) were prepared and characterized
y spectroscopic methods. A mixture of substituted phenol
37.4 mmol), p-ﬂuorobenzaldehyde (37.4 mmol) and potassium
arbonate (38.8 mmol) in N,N-dimethylformamide (40 ml)  was
eﬂuxed for 16–18 h under nitrogen. After cooling, the prod-
ct was extracted from the reaction mixture and puriﬁed by
hromatography. Equimolar quantities (0.01 mol) of 4-substituted
enzaldehydes and isoniazide were dissolved in warm ethanol
ontaining 0.5 ml  of glacial acetic acid. The reaction mixture wascal Macromolecules 82 (2016) 663–670
reﬂuxed for 4–6 h and set aside. The resultant solid was washed
with ethanol and recrystallized from 90% ethanol.
Preparation of cis-[bis (S)dichlororuthenium(II)] cis-[Ru(S)2Cl2]
(where S = 2,2′-bipyridine/1,10-phenanthroline): [28]
General procedure for preparing-[Ru(S)2(L)Cl2] (where S = 1,10-
phenanthroline/2,2′-bipyridine); [21] where L = 4-CF3-pdc, 4-F-
pdc, 4-OH-pdc, pbinh:
4-CF3-pdc: Yield 75%. FTIR (KBr, cm−1): 3428–3342 (NH2 & NH),
2986 (C H), 1542 (C N), 1325 (C S). max nm (MeOH): 220, 296
and 398. Mp  232–234 ◦C. Anal. calcd for C15H13F3N4S: C, 53.25; H,
3.87; N, 16.56. Found: C, 53.19; H, 3.78; N, 16.48. 1H NMR (DMSO-
d6): ı 10.22 (s, 1H, NH), 7.64 (d, 1H), 7.45 (d, 1H), 7.38–7.28 (dd,
2H), 7.26 (d, 2H,), 7.17 (s, 1H, pyrrole-H5), 7.05 (d, 1H, pyrazoles),
6.92 (t, 1H, Pyrrole ring), 3.82 (dd, 1H), 3.73 (dd, 1H), 3.34 (dd, 1H)
(ESI-MS: m/z 338 (100)).
4-F-pdc: Yield 82%. FTIR (KBr, cm−1): 3398–3314 (NH2 & NH),
2935 (C H), 1532 (C N), 1332 (C S). max nm (MeOH): 200, 306,
349. Mp  216–218 ◦C. Calcd. for C14H13N4SF: C, 58.32; H, 4.54; N,
19.43. Found C, 58.24; H, 4.48; N, 19.36%. 1H NMR (DMSO-d6): ı
10.06 (s, 1H, NH), 7.85 (d, 1H), 7.56 (d, 1H), 7.36 (d, 1H), 7.32–7.26
(m,  3H) 7.22 (s, 1H, pyrrole-H5), 7.10 (d, 1H, pyrazoles), 6.88 (t, 1H,
Pyrrole ring), 3.74 (dd, 1H), 3.68 (dd, 1H), 3.45 (dd, 1H) ESI-MS: m/z
288 (100).
4-OH-pdc: Yield 84%. FTIR (KBr, cm−1): 3512 (OH) 3406–3386
(NH2 & NH), 3012 (C H), 1538 (C N), 1328 (C S). max nm (MeOH):
198, 302, 374. Mp  198–199 ◦C. Anal. calcd. for C14H14N4OS: C,
58.72; H, 4.93; N, 19.57. Found: C, 58.68; H, 4.88; N, 19.52. 1H NMR
(DMSO-d6): ı 10.32 (s, 1H, NH), 7.58 (d, 1H), 7.46 (d, 1H), 7.40–7.26
(dd, 2H), 7.18 (d, 2H,), 7.06 (s, 1H, pyrrole-H5), 7.02 (d, 1H, pyra-
zoles), 6.94 (t, 1H, Pyrrole ring), 5.32 (s, 1H), 3.82 (dd, 1H), 3.70 (dd,
1H), 3.34 (dd, 1H) ESI-MS: m/z 286 (100).
4-Cl-pbinh: Yield 72%. FTIR (KBr, cm−1): 3308 (N H), 3082
(C H), 1680 (C O), 1612 (N H). max nm (MeOH): 202, 298 and
368. Mp  204–206 ◦C Anal. calcd. for C19H14N3O2Cl: C, 64.87; H, 4.01;
N, 11.94. Found: C, 64.78; H, 3.98; N, 11.86. 1H NMR  (DMSO-d6): ı
8.92 (s, 1H, CH N), 8.88 (s, 1H), 8.36 (s, 1H), 8.02 (s, 1H), 7.94 (dd,
1H), 7.84–7.78 (d, 2H), 7.64 (s, 1H), 7.58 (d, 2H, J = 8.7 Hz), 7.42–7.36
(d, 2H), 7.16 (s, 1H), 7.06 (s, 1H). ESI-MS: m/z 351 (100).
[Ru(Phen)2(4-CF3-pdc)]2+Cl2 (Ru-1): Yield 52%. FTIR (KBr,
cm−1): 3430–3298 (NH2 and NH), 2974 (C H), 1540 (C N), 1332
(C S). max nm (MeOH): 202, 278, 326, 398 and 454. Anal. calcd. for
C39H29N8RuSFCl2: C, 53.80; H, 3.36; N, 12.87. Found: C, 53.74; H,
3.32; N, 12.78. 1H NMR  (DMSO-d6): ı 10.16 (s, 1H), 8.92 (s, 1H), 8.84
(d, 1H, J = 4.9 Hz), 8.82 (s, 1H), 8.76 (s, 1H), 8.72 (t, 2H, J = 5.0 Hz),
8.64 (s, 1H), 8.52 (d, 1H, J = 8.7 Hz), 8.44–8.22 (m, 3H), 8.18–8.02
(m,  2H), 7.98 (d, 1H, J = 8.4 Hz), 7.78 (d, 1H, J = 8.4 Hz) 7.64–7.50 (m,
2H) 7.44 (d, 1H, J = 5.0 Hz), 7.30–7.22 (m,  3H), 6.96 (s, 1H), 6.84 (s,
1H), 6.72 (d, 2H, J = 8.7 Hz), 3.72 (dd, 1H), 3.69 (dd, 1H) 3.54 (d,
1H). 13C NMR  (DMSO-d6): 181.4 (s, 1C, C S), 159.8 (s, 1C), 150.2 (s,
1C, CH N), 149.4 (s, 1C, CH N), 148.8 (s, 1C, CH N), 147.2 (s, 1C,
CH N), 143.4 (s, 1C), 139.0 (s, 1C), 137.6 (s, 1C), 137.2 (s, 1C), 136.2
(s, 1C), 135.6 (s, 1C), 134.4 (s, 1C), 133.8 (s, 1C), 132.4 (s, 1C), 130.2
(s, 1C), 129.4 (s, 1C), 127.8 (s, 1C), 127.2 (s, 1C), 126.8 (s, 1C), 126.2
(s, 1C), 125.8 (s, 1C), 125.4 (s, 1C), 125.0 (s, 1C), 124.6 (s, 1C), 124.2
(s, 1C), 124.0 (s, 1C), 123.8 (s, 1C), 123.2 (s, 1C), 122.4 (s, 1C), 122.0
(s, 1C), 121.4 (s, 1C), 119.6 (s, 1C), 118.2 (s, 1C), 109.4 (s, 1C), 108.2
(s, 1C), 107.8 (s, 1C), 58.4 (s, 1C), 37.6 (s, 1C). FAB-MS (m-NBA); 800
[Ru(phen)2(4-CF3-pdc)], 461 [Ru(phen)2], 338 [4-CF3-pdc].
[Ru(bpy)2(4-CF3-pdc)]2+Cl2 (Ru-2): Yield 49%. FTIR (KBr, cm−1):
3426–3352 (NH2 and NH), 3004 (C H), 1538 (C N), 1424 (N H),
1328 (C S). max nm (MeOH): 196, 250, 292, 314, 380 and 445.
Anal. calcd. for C35H29N8RuSCl2: C, 51.10; H, 3.55; N, 13.62. Found:
C, 51.02; H, 3.50; N, 13.58. 1H NMR  (DMSO-d6): ı 10.08 (s, 1H), 9.01
(s, 1H), 8.96 (d, 1H, J = 4.9 Hz), 8.92 (s, 1H), 8.88(s, 1H), 8.78 (s, 1H),
8.72–8.66 (m,  4H, J = 5.0 Hz), 8.62 (s, 1H), 8.50 (d, 1H, J = 8.7 Hz),
8.38–8.22 (m,  4H), 7.92 (d, 1H, J = 8.4 Hz), 7.74 (d, 1H, J = 8.4 Hz)
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.58–7.36 (m,  2H) 7.30 (d, 1H, J = 5.0 Hz), 7.22 (m,  3H), 6.96 (s, 1H),
.82 (s, 1H), 6.72 (d, 2H, J = 8.7 Hz), 6.10 (s, 1H), 3.74 (dd, 1H), 3.66
dd, 1H) 3.52 (d, 1H). 13C NMR  (DMSO-d6): 179.6 (s, 1C, C S), 157.6
s, 1C), 149.4 (s, 1C, CH N), 147.8 (s, 1C, CH N), 147.2 (s, 1C, CH N),
46.0 (s, 1C, CH N), 143.6 (s, 1C), 139.6 (s, 1C), 138.0 (s, 1C), 136.2
s, 1C), 135.0 (s, 1C), 132.4 (s, 1C), 131.2 (s, 1C), 130.8 (s, 1C), 129.6
s, 1C), 129.2 (s, 1C), 129.0 (s, 1C), 127.6 (s, 1C), 126.2 (s, 1C), 125.4
s, 1C), 124.0 (s, 1C), 123.2 (s, 1C), 122.4 (s, 1C), 121.2 (s, 1C), 120.4
S, 1C), 119.2 (s, 1C), 118.4 (s, 1C), 117.6 (s, 1C), 116.0 (s, 1C), 115.4
s, 1C), 109.6 (s, 1C), 108.2 (s, 1C), 106.4 (s, 1C), 57.2 (s, 1C), 38.4 (s,
C). FAB-MS (m-NBA); 752 [Ru(bpy)2(4-CF3-pdc)], 413 [Ru(bpy)2],
38 [4-CF3-pdc].
[Ru(Phen)2(4-F-pdc)]2+Cl2 (Ru 3): Yield 46%, black crystals, FTIR
KBr, cm−1): 3398–3224 (NH2 and NH), 2988 (C H), 1545 (C N),
334 (C S). Calcd. for C38H29N8RuSFCl2: C, 55.61; H, 3.56; N, 13.65.
ound C, 55.58; H, 3.48, N, 13.58%. 1H NMR  (DMSO-d6): ı 10.32 (s,
H), 8.96 (s, 1H), 8.92 (s, 1H), 8.80 (s, 1H), 8.74 (s, 1H), 8.66–8.60
t, 2H, J = 5.0 Hz), 8.52 (s, 1H), 8.40 (d, 1H, J = 8.7 Hz), 8.34–8.20 (m,
H), 8.10–7.96 (m,  2H), 7.88 (d, 1H, J = 8.4 Hz), 7.72 (d, 1H, J = 8.4 Hz)
.64–7.50 (m,  2H) 7.42 (d, 1H, J = 5.0 Hz), 7.36–7.28 (m,  3H), 6.92 (s,
H), 6.84 (s, 1H), 6.68 (d, 2H, J = 8.7 Hz), 3.80 (dd, 1H), 3.68 (dd,
H) 3.56 (d, 1H). FAB-MS (m-NBA); 750 [Ru(phen)2(4-F-pdc)], 461
Ru(phen)2], 288 [4-F-pdc].
[Ru(bpy)2(4-F-pdc)]2+Cl2 (Ru 4): Yield 50%, black crystals, FTIR
KBr, cm−1): 3404–3308 (NH2 and NH), 2992 (C H), 1534 (C N),
328 (C S). Calcd. for C34H29N8RuSFCl2: C, 52.85; H, 3.78; N, 14.50.
ound C, 52.78; H, 3.74; N, 14.42%. 1H NMR  (DMSO-d6): ı 10.28 (s,
H), 8.94 (s, 1H), 8.88 (s, 1H), 8.80 (s, 1H), 8.76 (s, 1H), 8.72 (s,
H), 8.66–8.54 (m,  4H, J = 5.0 Hz), 8.42 (s, 1H), 8.38–8.32 (d, 1H,
 = 8.7 Hz), 8.30–8.22 (m,  4H), 7.96 (d, 1H, J = 8.4 Hz), 7.74 (d, 1H,
 = 8.4 Hz) 7.42–7.30 (m,  3H) 7.22 (d, 1H, J = 5.0 Hz), 6.94 (s, 1H),
.82 (s, 1H), 6.68 (d, 2H, J = 8.7 Hz), 3.92 (dd, 1H), 3.68 (dd, 1H) 3.560
d, 1H). FAB-MS (m-NBA); 702[Ru(bpy)2(4-F-pdc)], 413 [Ru(bpy)2],
88 [4-F-pdc].
[Ru(Phen)2(4-OH-pdc)]2+Cl2 (Ru-5): Yield 48%, black crystals,
TIR (KBr, cm−1): 3508 (OH), 3422–3394 (NH2 and NH), 3016
C H), 1522 (C N), 1332 (C S). max nm (MeOH): 202, 254, 299,
45, 405 and 458. Anal. calcd. for C38H30N8ORuSCl2: C, 55.75; H,
.69; N, 13.69. Found: C, 55.66; H, 3.62; N, 13.64. 1H NMR  (DMSO-
6): ı 10.25 (s, 1H), 9.02 (s, 1H), 8.96 (s, 1H), 8.88 (s, 1H), 8.82 (s, 1H),
.76–8.70 (dd, 2H, J = 5.0 Hz), 8.64. (s, 1H), 8.38 (d, 1H, J = 8.7 Hz),
.32–8.24 (m,  3H), 8.12–7.96 (m,  2H), 7.92 (d, 1H, J = 8.4 Hz),
.62 (d, 1H, J = 8.4 Hz) 7.50–7.36 (m,  2H) 7.30 (d, 1H, J = 5.0 Hz),
.24–7.16 (m,  3H), 6.92 (s, 1H), 6.80 (s, 1H), 6.62 (d, 2H, J = 8.7 Hz),
.28 (s, 1H), 3.90 (dd, 1H), 3.68 (dd, 1H) 3.48 (dd, 1H). FAB-
S (m-NBA); 748 [Ru(phen)2(4-OH-pdc)], 461 [Ru(phen)2], 286
4-OH-pdc].
[Ru(bpy)2(4-OH-pdc)]2+Cl2 (Ru-6): Yield 48%, black crystals,
TIR (KBr, cm−1): 3468–3322 (NH2 and NH), 2994 (C H), 1538
C N), 1325 (C S). max nm (MeOH): 204, 270, 395 and 452. Anal.
alcd. for C34H30N8ORuS: C, 58.36; H, 4.32; N, 16.01. Found: C,
8.28; H, 4.30; N, 15.94. 1H NMR  (DMSO-d6): ı 10.04 (s, 1H), 8.98
s, 1H), 8.90 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.68 (s, 1H), 8.62 (m,
H, J = 5.0 Hz), 8.54 (s, 1H), 8.42 (d, 1H, J = 8.7 Hz), 8.36–8.22 (m, 4H),
.06 (d, 1H, J = 8.4 Hz), 7.88 (d, 1H, J = 8.4 Hz) 7.64–7.42 (m,  2H) 7.26
d, 1H, J = 5.0 Hz), 6.98 (s, 1H), 6.86 (s, 1H), 6.64 (d, 2H, J = 8.7 Hz),
.14 (s, 1H), 3.84 (dd, 1H) 3.60(s, 1H) 3.56 (d, 1H). FAB-MS (mNBA);
00 [Ru(bpy)2(4-OH-pdc)], 413 [Ru(bpy)2], 286 [4-OH-pdc].
[Ru(Phen)2(4-Cl-pbinh)]2+Cl2 (Ru-7): Yield 52%, black crystals,
R (KBr, cm−1): 3326 (N H), 3008 (C H), 1680 (C O), 1620 (N H).
alcd. for C43H30N7O2RuCl3: C, 58.41; H, 3.42; N, 11.09. Found C,
8.36; H, 3.38; N, 11.04%. 1H NMR  (DMSO-d6): ı 9.14 (s, 1H), 8.96 (s,
H), 8.90 (s, 1H), 8.85 (s, 1H), 8.80 (s, 1H), 8.75 (s, 1H), 8.64 (d, 1H,
 = 8.4 Hz), 8.38–8.26 (d, 2H, J = 8.6 Hz), 8.22–8.08 (m,  3H), 8.12–8.04
m,  3H), 7.92 (d, 2H, J = 5.1 Hz), 7.78–7.72 (dd, 2H), 7.68–7.54 (m,
H), 7.52 (s, 1H), 7.44–7.40 (m,  2H), 7.28–7.22 (m,  2H), 7.14 (dd,cal Macromolecules 82 (2016) 663–670 665
2H), 7.08 (s, 1H), 7.02 (s, 1H). FAB-MS (mNBA); 812 [Ru(phen)2(4-
Cl-pbinh)], 461 [Ru(phen)2], 351 [4-Cl-pbinh].
[Ru(bpy)2(4-Cl-pbinh)]2+Cl2 (Ru-8): Yield 46%, black crystals, IR
(KBr, cm−1): 3364 (N H), 2998 (C H), 1682 (C O), 1608 (N H).
Calcd. for C39H30N7O2RuCl3: C, 56.02; H, 3.62; N, 11.73. Found C,
55.94; H, 3.58; N, 11.69%. 1H NMR  (DMSO-d6): ı 9.06 (s, 1H), 9.02
(s, 1H), 8.94 (s, 1H), 8.82 (s, 1H), 8.75 (s, 1H), 8.70 (s, 1H), 8.64 (s,
1H), 8.48 (s, 1H), 8.24–8.12 (m,  4H), 8.08–8.00 (m,  3H), 7.98 (d,
2H, J = 5.1 Hz), 7.84–7.72 (m,  4H), 7.68–7.52 (m, 3H), 7.50–7.42 (dd,
2H), 7.38–7.32 (m,  2H), 7.25–7.12 (m,  2H). FAB-MS (mNBA); 764
[Ru(bpy)2(pbinh)], 413 [Ru(bpy)2], 351 [4-Cl-pbinh].
3. Results and discussion
3.1. Chemistry
The synthesis of ligands pdc (1a–1c) was accomplished as
outlined in Scheme 1. Starting from compound which can be
synthesized according to the procedure described in previous
literature [29]. The reaction of the starting material various p-
substituted acetophenones with pyrrole-2-aldehyde under the
reaction conditions of NaOH gave a pyrrole derivatives. Treatment
of these compounds with thiosemicarbazide in alcohol gave a
ﬁnal ligands (1a–1c). The phenoxy benzyl isonicotinyl hydrazones
were prepared as shown in Scheme 2. Synthetic strategy shows
the (Schemes 3 and 4) details of the adopted for the synthesis
of homoleptic ruthenium complexes. Ruthenium trichloride tri-
hydrate undergoes reduction in a number of organic solvents. In
this homoleptic chelate the ﬁrst ligand to enter the complex in
a stepwise assembly were 2,2′-bipyridine/1,10-phenanthroline
respectively. Ruthenium trichloride trihydrate was reﬂuxed in DMF
in the presence of 2,2′-bipyridine/1,10-phenanthroline in excess
of the stoichiometric amount, which afforded the ﬁnal product cis-
bis(2,2-bipyridine/1,10-phenanthroline)-dichlororuthenium(II)
(Scheme 3). The introduction of the third ligand (1a–1d) was
carried out in presence of alcohol (Scheme 4) afforded the ﬁnal
product. In order to obtain products of high purity, it was necessary
to use column chromatography. Column chromatography was
performed with silica gel (60–120 mesh) as the support with
CHCl3 CH3OH as the eluate.
The structures of ligands (1a–1d) were determined by UV, FT-
IR, 1H NMR, 13C NMR, Elemental analysis and mass spectroscopy.
For pyrazole ligand 4-CF3-pdc (1a) the vibration bands were exhib-
ited at 3428 for NH2, 3342 for NH, 2986 for CH aliphatic, 1542 for
C N, 1325 for C S. In 1H NMR  of (1a) there are well resolved res-
onance peak at low Field at 10.22 (1H, s, NH), 7.64–6.92 for Ar H
and pyrrole, pyrazole hydrogens, 3.82–3.73 (2H, CH2), 2.41 ı ppm
respectively. The IR spectra of complex (Ru-1) [Ru(phen)2 4-CF3-
pdc]Cl2 the IR bands observed at 3430 for NH2, 3298 for NH, 2974
for CH aliphatic, 1540 for C N, 1332 for C S. A comparison of the IR
spectra of the ligands is coordinated to the metal ion by imine nitro-
gen and Sulphr atom, which was conﬁrmed by the IR Spectra. Which
indicates changes in vibrational frequency C S. In 1H NMR  spectra
of complexes there are well resolved resonance peak at low Field
at 10.16 (1H, s, NH), 8.92–8.76 (4H, CH N), 8.72–6.72 for Ar H
and pyrrole and pyrazole hydrogens, 3.72–3.69 (2H, CH2) ı ppm
respectively. These complexes showed broad and intense visible
bands between 350 and 450 nm due to metal to ligand charge trans-
fer transition. In the UV region, the band at 290 and 310 nm were
assigned to phenanthroline ligand. The same transition was found
in free phenathroline at 280 nm,  so that coordination of the ligand
results in redshift in the transition energy. There were also two
shoulders at 390 and 500 nm,  which were tentatively attributed to
a metal to ligand charge transition involving phenanthroline ligand.
The FAB-MS of the prepared complexes showed mass spectra for
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Scheme 1. Synthesis of ligands R-PDC (1a–1c).
Scheme 2. Synthesis of ligand 4-Cl-PBINH (2a).Scheme 3. Synthesis of [Ru(S)2]Cl2.Scheme 4. Synthesis of [Ru(S)2(L)]Cl2.
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heir respective masses. The spectrum showed numerous peaks
epresenting successive degradation of the molecules. The based on
he above observations the proposed structures of the complexes
re octahedral coordination shown in Fig. 1.
.2. DNA binding studies: [30]
.2.1. Electronic absorption spectroscopy
Electronic absorption titration experiments were performed
ith a ﬁxed concentration of ruthenium complex (25 M)  but the
ariable nucleotide concentration ranging from 0 to 25 M and
fter each addition of DNA to the ruthenium complex, the read-
ngs were noted. The electronic absorption spectra of complexes
Ru-1 to Ru-8) consist of two or three well-resolved bands in the
ange of 200–450 nm.  The high energy absorption band appeared
n the spectra of respective complexes below 300 nm are assigned
o  → * intra ligand charge transfer transitions and the band
hat were found around 400 nm are assigned to ligand-to-metal
harge transfer (LMCT). Upon the addition of DNA, the above bands
orresponding to complexes showed signiﬁcant hypochromism
ccompanied with a red shift. It suggested that the complexes used
n this study showed strong binding to DNA in an intercalative
ode.
.2.1.1. Competitive binding ﬂuorescence measurements. The appar-
nt binding constant (Kapp) of the complexes was determined by
 ﬂuorescence spectral technique using ethidium bromide (EB)-
ound CT-DNA solution in Tris–HCl buffer (pH 7.10). The changes
n ﬂuorescence intensities at 605 nm (545 nm excitation) of EB
ound to DNA were measured with respect to concentration of
he complex. Steady-state competitive binding experiments using
omplexes 1, 2 and 3 as quenchers were undertaken to get further
roof for the binding of the complexes to DNA. Ethidium bromide
EB) is a planar cationic dye which is widely used as a sensitive ﬂu-
rescence probe for native DNA. EB emits intense ﬂuorescent light
n the presence of DNA due to its strong intercalation between the
djacent DNA base pairs. The displacement technique is based on
he decrease of ﬂuorescence resulting from the displacement of
B from a DNA sequence by a quencher and the quenching is due
o the reduction of the number of binding sites on the DNA that
s available to the EB. As the concentration of the ruthenium com-
lexes increases, the ﬂuorescence spectra showed a signiﬁcant shift
red) in wavelength with a reduction in the ﬂuorescence intensity
learly indicating that the EB molecules are displaced from theirR-pdc)]2+ and [Ru(phen)2(pbinh)]2+.
DNA binding sites and are replaced by the ruthenium complexes
under investigation.
3.2.2. DNA cleavage experiments [31]
In each experiment, the extent of DNA cleavage was moni-
tored by agarose gel electrophoresis. A solution containing 25 L of
pUC19 DNA (1 g), HCl (50 mM,  pH 7.5), NaCl (50 mM),  the ruthe-
nium complex (30 M),  and H2O2 (60 M)  was  incubated for 1–4 h
at 37 Subsequently, 4 L of 6X DNA loading buffer containing 0.25%
bromophenol blue, 0.25% xylene cyanol and 60% glycerol was added
to the reaction mixture and loaded onto a 1% agarose gel containing
1.0 g/ml of ethidium bromide. The electrophoresis was performed
at 5 V/cm for 2 h in a TBE buffer. The bands were visualized under
UV light and photographed. The cleavage efﬁciencies were mea-
sured by determination of the ability of each complex to convert
the supercoiled DNA (SC) to the nicked circular form (NC). The inter-
action of plasmid pUC19 DNA with complexes was studied in order
to determine the efﬁciencies with which these complexes sensi-
tize DNA cleavage. This objective was achieved by monitoring the
transition from the naturally occurring, covalently closed circular
form (Form I) to the nicked circular relaxed form (Form II) by means
of gel electrophoresis of the plasmid. The cleavage of supercoiled
(SC) DNA (Form I) to the nicked circular (NC) DNA (Form II) was
observed for all the complexes regardless of different incubation
periods and variation of the concentrations of the test solutions. The
results of the experiments carried out in the concentration range
25–55 M for all the complexes after 1 and 2 h of incubation are dis-
played in (supplementary information Figs. A1–A4) Examination of
these ﬁgures revealed that there observed no signiﬁcant cleavage
for controls.
3.2.3. Protein binding studies [32]
The binding of metal complexes with bovine serum albumin
(BSA) were studied using ﬂuorescence spectra recorded at a ﬁxed
excitation wavelength corresponding to bovine serum albumin
(BSA) as 280 nm and monitoring the emission at 345 nm.  The exci-
tation and emission slit widths and scan rates were constantly
maintained for all the experiments.
3.2.3.1. Fluorescence quenching of BSA by ruthenium complexes.
Qualitative analysis of chemical compounds bound to BSA can
be undertaken by examining the respective ﬂuorescence spec-
tra. Generally, the ﬂuorescence of a protein is caused by
three intrinsic characteristics of the protein, namely tryptophan,
tyrosine, and phenylalanine residues. Fluorescence quenching
668 S. Thota et al. / International Journal of Biologi
Fig. 2. Synchronous spectra of BSA (1 × 10−6 M)  as a function of concentration of
t
d
a
r
s
i
e
q
3
che  ruthenium complex 3 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 × 10−6 M)  with wavelength
ifference of   = 15 nm (A). Arrow indicates the emission intensity decreases
ccompanied by red shift (A).
efers to any process, which decreases the ﬂuorescence inten-
ity of a ﬂuorophore due to variety of molecular interactions
ncluding excited state reactions, molecular rearrangements,
nergy transfer, ground-state complex formation, and collision
uenching.
.2.3.2. Characteristics of synchronous ﬂuorescence spectra. The syn-
hronous ﬂuorescence spectra of BSA with various concentrations
Fig. 3. Structure activity relationshipcal Macromolecules 82 (2016) 663–670
of ruthenium complexes recorded at   = 15 nm and   = 60 nm
are shown in Fig. 2. From the spectra, we understand that an
increase in the concentration of ruthenium complexes 1 and 3
resulted in a decrease in the intensity of the synchronous ﬂu-
orescence spectral band corresponding to tyrosine residue with
a slight red-shift. However, after the addition of complex 2 to
BSA there occurred an increase in the intensity of the above
said band with a slight red shift as observed for the complexes
1 and 3. In addition to this, a gradual decrease of ﬂuorescence
intensity of tryptophan residues together with slight blue-shift
of emission wavelength were also observed with complexes 1–3.
These experimental results indicate that the ruthenium complexes
do affect the microenvironment of both tyrosine and tryptophan
residues during the binding process and synchronous measure-
ments conﬁrmed the effective binding of all the complexes with
BSA.
3.2.4. Cytotoxic activity [33]
The 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) cell proliferation assay was  employed to evaluate the
cytotoxic activity of the synthesized compounds against 5 cancer
cell lines murine leukemia L1210, human lymphocyte CEM, human
epithelial cervical carcinoma HeLa, BEL-7402 and Molt4/C8. Cells
were incubated with the ruthenium complexes at various con-
centrations for 72 h, and their IC50 values were determined and
summaries in Table 1. Cisplatin were taken as a reference drug.
The results were expressed as the average of triplicate assays.
Comparison of structure activity relationships (Fig. 3) with ruthe-
nium complexes bearing pdc ligands (Ru-1 to Ru-6) displayed
the better cytotoxicity comparison with the ruthenium complexes
bearing isonicotinyl hydrazone ligand (Ru-7 to Ru-8). On compari-
son to ruthenium complexes the ligands displayed the cytotoxicty
at higher mol/L concentration. On comparison with other ruthe-
nium complexes (e.g. NAMI-A & KP1019) these reported ruthenium
complexes displayed the cytotoxicity at lower mol/L concentra-
tion.
 of [Ru(phen)2(R-pbinh)]2+Cl2.
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Table  1
Cytotoxic studies of ligands and ruthenium complexes.
Comp. code IC50a (mol/L)
BEL7402 L1210 HL60 Molt4/C8 CEM
4-CF3-pdc 176 ± 34 >250 152 ± 16 188 ± 12 >250
4-F-pdc 194 ± 06 222 ± 12 138 ± 08 >250 125 ± 08
4-OH-pdc 138 ± 12 154 ± 18 122 ± 06 118 ± 12 198 ± 06
4-Cl-pbinh 220 ± 14 196 ± 04 174 ± 12 186 ± 02 >250
Ru-1  0.82 ± 0.4 1.2 ± 0.8 0.52 ± 0.02 0.64 ± 0.06 0.72 ± 0.4
Ru-2  0.92 ± 0.06 0.68 ± 0.2 0.54 ± 0.6 0.48 ± 0.04 0.62 ± 0.08
Ru-3  4.2 ± 0.8 8.6 ± 1.2 3.6 ± 0.08 2.8 ± 0.06 2.2 ± 0.4
Ru-4  3.8 ± 0.08 5.0 ± 0.8 7.2 ± 0.42 5.2 ± 0.6 4.8 ± 0.22
Ru-5  0.88 ± 0.6 1.2 ± 02 0.58 ± 0.04 0.66 ± 0.02 0.82 ± 0.4
Ru-6  0.92 ± 0.8 0.84 ± 0.04 0.68 ± 0.2 0.94 ± 0.04 0.62 ± 0.8
Ru-7  3.6 ± 0.08 7.4 ± 0.6 6.6 ± 1.2 2.5 ± 0.4 6.4 ± 0.06
Ru-8  4.2 ± 0.6 6.8 ± 0.2 3.6 ± 0.08 2.8 ± 0.6 7.4 ± 0.8
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a 50% inhibitory concentration, required to inhibit tumor cell proliferation by 50%
. Conclusion
The synthesis and characterization of a novel series of Ru(II)
omplexes (Ru-1 to Ru-8) bearing R-pbc & pbinh were evaluated.
ll the newly synthesized complexes were evaluated for DNA bind-
ng, DNA cleavage, protein binding and cytotoxicity studies. The
NA binding of ruthenium complexes examined by absorption and
uorescence spectral techniques revealed an intercalative interac-
ion between them and CT-DNA with binding constants ranging
rom 103 to 105 M−1. Among the 8 complexes tested for DNA cleav-
ge activity, Ru-5 effected almost complete conversion of pUC19
NA from the supercoiled form (Form I) to the nicked circular form
Form II). Binding of the ruthenium complexes with BSA monitored
y UV–vis spectroscopy revealed the presence of static quench-
ng and the results of synchronous spectral studies indicated that
he complexes bound with BSA in both tyrosine and tryptophan
esidues. These ruthenium complexes show good binding to calf
hymus DNA and most exhibit efﬁcient DNA cleavage upon irra-
iation via a mechanistic pathway involving formation of singlet
xygen as the reactive species. These results suggest that both ancil-
ary ligand and intercalative ligand inﬂuence the binding of these
omplexes to DNA. The majority of the ruthenium complexes pos-
essed antiproliferative activities against all the tested cancer cell
ines, while the BEL 7402, HL60, Molt4/C8 and CEM cell lines were
ore sensitive in response to the growth inhibition than L1210 cell
ine. It is of notice that most of the complexes exhibited more potent
ytotoxic activity than the reference drug cisplatin against HL60
ell line. Complex Ru-2 was the most active and 2-fold more potent
han cisplatin against L1210 with IC50 value of 0.68 mol/L, but was
ess potent against BEL7402 cell line. Complex Ru-1 was the most
ffective against HL60 cell with IC50 value of 0.52 mol/L, showed
eak activity against L1210. Complex Ru-5 was the most effec-
ive against HL60 cell with IC50 value of 0.58 mol/L, showed weak
ctivity against L1210. These differences suggested that our com-
lexes displayed selective cytotoxicity in contrast to being a general
road cytotoxic agent. These preliminary results are beneﬁcial for
urther lead optimization.
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